Mesangial cell (MC) proliferation and extracellular matrix expansion are involved in the pathogenesis of glomerulosclerosis and renal failure. In vitro, PDGF and basic fibroblast growth factor (bFGF) regulate MC proliferation and/or matrix production. To elucidate the role of PDGF and bFGF in vivo, equimolar concentrations of recombinant PDGF-BB or bFGF or vehicle were infused intravenously into rats over a 7-d period. Rats were either nonmanipulated ("normals") or had received a subnephritogenic dose of anti-MC antibody ("anti-Thy 1.1 rats") before the infusion period. Glomerular cell proliferation (anti-proliferating cell nuclear antigen immunostaining) on days 2, 4, and 7 was unchanged in vehicle-infused normals or anti-Thy 1.1 rats. PDGF infusion increased glomerular cell proliferation 32-fold in anti-Thy 1.1 rats and an 11-fold in normals on day 2. bFGF increased glomerular cell proliferation fourfold in anti-Thy 1.1 rats but was ineffective in normals. Induction of cell proliferation in all kidneys was limited to the glomerulus. The majority of proliferating cells were identified as MC by double immunolabeling. No significant proteinuria, glomerular leukocyte, or platelet influx developed in any group. Glomerular matrix expansion with increased deposition of type IV collagen, laminin, and fibronectin, as well as upregulated laminin and collagen IV mRNA expression was confined to PDGF-infused anti-Thy 1.1 rats. These results show that PDGF and, to a lesser degree, bFGF are selective MC mitogens in vivo and that previous subclinical injury can enhance this MC response. The data thereby support a role of these cytokines in the pathogenesis of glomerulosclerosis. (J. Clin. Invest. 1993Invest. .92:2952Invest. -2962
Introduction
Proliferation of intrinsic glomerular mesangial cells as well as expansion ofthe mesangial extracellular matrix are central features of numerous experimental and human glomerular diseases (1) (2) (3) . Both processes are thought to play an important role in the development of glomerular sclerosis and renal failure ( 1, 3) . Over the last five years, evidence has accumulated to link cytokines to the regulation of mesangial cell proliferation and matrix synthesis (reviewed in references 1 and 4). However, most of this evidence is correlative and a causal role of cytokines has been difficult to demonstrate.
We (5) , as well as others (6) , have recently outlined criteria to establish a role for a cytokine in mediating a specific biological effect in glomerular disease. These criteria include (a) the demonstration that the cytokine has the effect on target cells in vitro; (b) the demonstration that the cytokine is released or expressed in diseases and correlates with the proposed effect; (c) the demonstration that inhibition of the cytokine in vivo blocks the postulated effect of the cytokine in disease; and (d) the demonstration that administration of the cytokine in vivo (or overexpression in transgenic animals) reproduces the biological effect.
In the case of two cytokines, PDGF and basic fibroblast growth factor (bFGF),' a number of these criteria have been fulfilled and have linked them to mesangial cell proliferation and mesangial matrix accumulation: (a) Both PDGF (mainly the BB isoform) and bFGF exhibit potent mitogenic effects on cultured mesangial cells (7) (8) (9) (10) . PDGF has also been shown to be involved in the regulation oftheir matrix synthesis ( 11 ) . (b) Numerous reports have shown that glomerular PDGF synthesis and PDGF receptor expression are increased in both experimental and human mesangial proliferative diseases (reviewed in references 5 and 6). Recently, we have also presented evidence that glomerular bFGF release and synthesis are increased in the rat mesangial proliferative anti-Thy 1.1 nephritis model ( 10) . (c) Inhibition of PDGF with a neutralizing antibody led to significant reduction of both mesangial cell proliferation and matrix accumulation in the anti-Thy 1.1 model ( 12) .
In the present study, we have attempted to fulfill the fourth criterion, namely to show that the exogenous administration of PDGF or bFGF can induce biological effects in vivo. Previously, limited data of ours had shown that a single bolus injection of bFGF into rats that had received a previous subnephritogenic mesangial insult could induce low grade mesangial cell proliferation ( 10) . Subnephritogenic injury was defined as the maximal dose of anti-mesangial cell antibody (anti-Thy 1.1 / antithymocyte serum) that could be administered without inducing significant morphological changes in the glomeruli. In the present study, we have expanded on this observation and have analyzed the effects of a 1 -wk infusion of recombinant PDGF-BB and/or bFGF on glomerular cell proliferation and matrix accumulation. To evaluate the influence of the mesangial cell status on the cytokine responsiveness, we have investigated the effects of infusion of PDGF-BB and/or bFGF into both normal rats, as well as into rats that had previously received a subnephritogenic dose of antithymocyte serum (ATS). The results show that administration of PDGF-BB to normal rats and especially to rats injected with subnephritogenic doses of ATS can induce pronounced histological changes in the glomerulus, namely increased mesangial cell proliferation and mesangial matrix accumulation, resembling those observed in mesangial proliferative glomerulonephritis. On a molar basis, PDGF-BB was considerably more potent than bFGF. bFGF led to only mild mesangial cell proliferation in subnephritogenic ATS rats and did not induce significant changes in normal rats. The data thereby provide further evidence for a causal role ofbFGF and, in particular, PDGF in the mediation of mesangial cell proliferation and matrix expansion in vivo.
Methods
Experimental design. To evaluate the renal effects of PDGF and bFGF, 15 normal male Wistar rats (Simonson, Gilroy, CA) weighing 180-220 g received a 7-d intravenous infusion of either PDGF-BB (n = 4), bFGF (n = 3), PDGF-BB plus bFGF (n = 3), or vehicle (n = 5). In addition, we studied 26 Wistar rats that had received a single intravenous injection of a subnephritogenic dose of goat anti-rat thymocyte serum at 30 min after the start ofthe infusion period (subnephritogenic ATS rats) (infusion of PDGF-BB: n = 9; bFGF: n = 6; PDGF-BB plus bFGF: n = 5; vehicle: n = 6). The subnephritogenic dose of ATS (0.1 ml/ 100 g body wt as opposed to the regularly used dose of0.5 ml/ 100 g [13] ) was chosen as the maximum amount of ATS that could be administered without inducing an increase in the glomerularcell proliferation rate. Cytokines or vehicle, respectively, were continuously infused through a catheter in the left internal jugular vein with microosmotic pumps (filling volume = 200 Ml; delivery rate = I Mul/h) (Alzet Corp., Palo Alto, CA). 24-h urinary protein excretion was determined on days 1-2, 3-4, and 6-7 after the implantation ofthe pumps. Renal biopsies, as well as blood samples, for urea nitrogen and creatinine were obtained from each rat on days 2 and 4 and upon death (day 7) .
In each kidney biopsy, we evaluated the total glomerular cell number and the number of proliferating glomerular or tubulointerstitial cells (as defined by immunostaining for the proliferating cell nuclear antigen [PCNA] [13] (26) .
For all biopsies, negative controls consisted of substitution of the primary antibody with equivalent concentrations of an irrelevant murine monoclonal antibody or normal rabbit IgG.
Mean values per biopsy were calculated for the number of proliferating (PCNA+) cells and leukocytes per glomerular cross section (see comment above). To obtain mean numbers of proliferating cells and infiltrating leukocytes in the cortical tubulointerstitium, 30 grid fields measuring 0.1 mm2 each were evaluated. For the evaluation of the immunoperoxidase stains for a-smooth muscle actin, PDGF B-chain, PDGF receptor 3 subunit, bFGF and the various matrix proteins, each glomerulus was graded semiquantitatively as described previously (27) , and the mean score per biopsy was calculated. Each score reflects mainly changes in the extent rather than intensity of mesangial staining. 0: diffuse, very, weak or absent mesangial staining. No localized increases of staining. 1+: Diffuse, weak mesangial staining with < 25% of the glomerular tuft showing focally increased staining. 2+: 25-50% of the glomerular tuft demonstrating a focal, strong staining. 3+: 50-75% of the glomerular tuft stained strongly in a focal manner. 4+: > 75% of the glomerular tuft stained strongly.
Immunohistochemical double staining. Double immunostaining for the identification of the type of proliferating cells was performed as reported previously (28) by first staining the sections for proliferating cells with 19A2, an IgM monoclonal antibody to PCNA, followed by staining with the IgG1 monoclonal antibody OX-7 (Accurate Chemical Corp.), an antibody against the Thy 1.1 antigen present on the mesangial cell membrane. Cells were identified as proliferating mesangial cells if they showed positive nuclear staining for PCNA and if the nucleus was completely surrounded by cytoplasm or cell membrane positive for OX-7. Proliferating cells in which the PCNA-positive nucleus did not border on the cytoplasm or cell membrane positive for OX-7 were classified as nonmesangial. Proliferating (PCNA+) cells that could not be clearly identified as OX-7 positive or negative were considered nonclassifiable.
In situ hybridization for PDGF B chain. In situ hybridization was performed on 4-,um sections of biopsy tissue fixed in buffered 10%
formalin using a digoxigenin-labeled antisense cRNA probe for the murine PDGF B chain (derived from a cDNA kindly provided by Charles Stiles, Harvard University, Boston, MA) as described (29) .
Detection ofthe cRNA probe was performed with an alkaline phosphatase coupled antidigoxigenin antibody (Genius Nonradioactive Nucleic Acid Detection Kit; Boehringer-Mannheim GmbH, Mannheim, Germany) with subsequent color development. Controls consisted of hybridization with a sense probe to matched serial sections, by hybridization ofthe antisense probe to tissue sections that had been incubated with RNAse A before hybridization, or by deletion of the probe, antibody, or color solution (29) . Preparation ofglomerular RNA and Northern analysis. Glomeruli were isolated by differential sieving ( 15) . Total RNA was extracted from glomeruli either as described (PDGF receptor) (30) or with RNAzol BT after the manufacturer's instructions (Cinna/Biotecx Laboratories, Friendswood, TX) (laminin B2 chain). The latter RNA obtained was further purified by a LiCl precipitation as described elsewhere (28) . For Northern analysis, the RNA was denatured and 15 ,gg/lane were electrophoresed through a formaldehyde/agarose gel and transferred to a nylon filter (Hybond NT; Amersham Corp., Arlington Heights, IL) as described ( 15 All probes were labeled with [a-32P]deoxycytidine 5-triphosphate (3,000 Ci/mmol, New England Nuclear, Boston, MA) by random primer extension. Positive controls included total RNA isolated from murine BALB/c 3T3 fibroblasts (PDGF receptor ,3 subunit) and glomeruli at 5 d after the induction of anti-Thy 1.1 glomerulonephritis in rats (laminin B2 chain).
To quantitate the amount of mRNA for each sample, membranes were prehybridized and hybridized as described ( 15 ) and autoradiograms were obtained and signal intensity was determined by PhophorImagerN analysis (Molecular Dynamics, Sunnyvale, CA) ( 15) . Total RNA in each sample was then determined by reprobing with a cDNA specific for 28S ribosomal RNA. All Northern analyses were repeated two to three times with glomerular RNA preparations obtained from different sets of animals. Alternatively, dot blots were prepared as described (28) and analyzed using the same procedure as described above.
Miscellaneous measurements. Urinary protein was measured by a method using sulfosalicylic acid (34) with a whole serum standard (Lab Trol; Dade Diagnostics, Aquado, Puerto Rico). Urea nitrogen and creatinine were measured in serum using an autoanalyzer (Beckman Instruments, Brea, CA).
Statistical analysis. All values are expressed as mean±SD. Statistical significance (defined as P < 0.05) was evaluated using the Student's t test or one-way ANOVA with modified t tests performed using the Bonferroni correction (35).
Results PDGF-BB infusion selectively induces glomerular hyperplasia in normal rats. PAS staining of renal biopsies obtained from normal rats infused with PDGF-BB (28 ng/min) or equimolar concentrations of PDGF-BB (28 ng/min) and bFGF (17 ng/ min) revealed mild glomerular hypercellularity with increased total cell counts ( Fig. 1) , while no changes were noted in the tubulointerstitium and vessels. Renal biopsies of rats infused with bFGF ( 17 ng/min) or vehicle had a normal appearance and normal glomerular cell counts (Fig. 1) . No synergistic effect between PDGF-BB and bFGF was observed (Fig. 1) . The number of proliferating glomerular cells increased up to eightfold in PDGF-BB infused rats, but not in bFGF-infused rats (Fig. 1) . Again, no further increase was observed when PDGF-BB and bFGF were combined (Fig. 1 ). Fig. 2 shows that the induction of cell proliferation in the kidneys of PDGF-BB-infused rats was confined to glomeruli, while no change was observed in the cortical tubulointerstitium (counts of proliferating cells in tubulointerstitial fields ranged from 1.1±0.4 to 1.5±0.9 PCNA+ cells/0.1 mm2 at any ofthe time points examined). Furthermore, neither PDGF-BB nor bFGF infusion led to an apparent increase in smooth muscle cell proliferation in larger vessels within the kidney.
Mitogenicity ofPDGF-BB and bFGF in vivo depends on the cellular status. To evaluate the effect of a minimal mesangial cell insult at the start of PDGF-BB and/or bFGF infusion, rats received a subnephritogenic dose of ATS. Fig. 1 confirms that this ATS dose was subnephritogenic, since it did not induce significant cell proliferation within the glomeruli of vehicle-infused rats. PAS-stained tissue sections obtained from these latter rats revealed rare mild mesangiolysis, which was, however, not sufficient to result in a significant increase ofthe mesangiolysis index. No other morphological abnormalities, increased glomerular influx of macrophages and platelets, or deposition of fibrin was noted in the subnephritogenic ATS rats (data not shown). Fig. 1 shows that in subnephritogenic ATS rats, total glomerular cellularity increased significantly during the infusion of PDGF-BB. This increase was higher than that observed in PDGF-BB-infused normal rats, although the difference between subnephritogenic ATS rats and normals was not statistically significant. bFGF infusion led to a significant increase of the total glomerular cellularity after 4 d in subnephritogenic ATS rats but not in normal rats (Fig. 1) . No synergism between the two cytokines was noted (Fig. 1 ) . Counting ofproliferating cells in the glomerulus revealed a < 32-fold increase in PDGF-BB-infused subnephritogenic ATS rats and an < 4.5-fold increase in bFGF infused rats (Fig. 1) . The changes observed were significantly higher than those observed in the corresponding normal rats (P < 0.05 subnephritogenic ATS rats vs normal rats) at all time points. Proliferating cell counts in glomeruli ofsubnephritogenic ATS rats infused with PDGF-BB plus bFGF were comparable to those receiving PDGF-BB alone (Fig. 1) .
As in the normal rats, the PDGF-BB-or bFGF-induced cell proliferation in the kidneys of subnephritogenic ATS rats was confined to the glomerulus (Fig. 2) , and no significant alterations were observed in the cortical tubulointerstitium or in large vessels.
In both normal and subnephritogenic ATS rats, the increases in glomerular PCNA-positive cells were associated with an increased frequency of mitoses in the glomeruli. In subnephritogenic ATS rats receiving PDGF-BB, occasional glomeruli contained more than one cell in mitosis (Fig. 3) . This was never observed in normal rats.
Increasedglomerular cellularity is mainly causedby mesangial cell proliferation. The increase in glomerular cellularity and cell proliferation was not caused by an infiltration of (proliferating) monocytes/macrophages, neutrophils, or lymphocytes, since these cell counts in glomeruli and tubulointerstitium remained normal in all groups (data not shown). Double immunostaining for PCNA and Thy 1.1 in PDGF-BB-infused normal or subnephritogenic ATS rats revealed that the majority of proliferating glomerular cells were mesangial cells (Fig.  4) . In contrast, in vehicle-infused rats, the majority ofproliferating glomerular cells were nonmesangial, presumably endothelial cells (36) . Similar to the cell proliferation induced by PDGF-BB, bFGF infusion also induced proliferation ofmainly mesangial cells in subnephritogenic ATS rats (Fig. 4) . No PCNA-positive nuclei were observed in locations corresponding to podocytes in any ofthe groups. Despite the induction of marked mesangial cell proliferation, no de novo expression of a-smooth muscle actin in glomeruli was noted in response to any treatment (data not shown).
Effects ofPDGF-BB and bFGF infusion on the expression of intrinsic mesangial cell growth factors. Normal immunostaining patterns in the kidney for PDGF B chain, PDGF receptor ,B subunit, and bFGF, using the same antibodies as used in the present study, have been reported previously ( 10, 22) and were not different in this study. Furthermore, the results of in situ hybridization for PDGF B-chain mRNA in glomeruli of normal rats were comparable to those reported previously (29) .
Neither PDGF nor bFGF infusion led to a significant increase of the glomerular immunostaining score for PDGF B chain (normal score = 0.8±0.2) in any ofthe groups. The fail- (Fig. 5) .
Neither PDGF nor bFGF infusion led to significant glomerular deposition ofplatelets or to thrombus formation (data not shown), both of which contain various mesangial cell mitogens ( 1, 4) .
Increased responsiveness ofsubnephritogenic A TS rats to PDGF is associated with a mild upregulation ofPDGF receptor. The injection of a subnephritogenic dose of ATS led to a small increase in the levels of glomerular PDGF receptor # subunit mRNA on day 2 after the injection (Table II) . As shown in Fig. 5 , there was also a small increase in the glomerular staining score for PDGF receptor # subunit after the administration ofsubnephritogenic ATS. In contrast, as noted above, no significant glomerular deposition of platelets or fibrinogen was observed in these latter rats. Fig. 6 shows that the renal responsiveness to PDGF-BB was still increased if a subnephritogenic dose of ATS was administered selectively into one kidney rather than systemically. In this case the response in the left kidney, which received the ATS, was significantly higher than in the right nonperfused kidney. [Day of n= (5) Effects ofPDGF-BB and bFGF infusion on glomerular matrix synthesis and expansion. Silver methenamine staining of the extracellular matrix failed to reveal a significant change from the normal staining pattern in the biopsies obtained from normal rats infused with PDGF-BB and/or bFGF. In subnephritogenic ATS rats, there was a minor increase in mesangial silver staining on day 7 in the PDGF-BB-infused rats but not in those receiving bFGF or vehicle (Fig. 7) . Immunohistochemical staining patterns using the antibodies against types I and IV collagen, laminin, and fibronectin in normal rats have been reported previously (27) , and were not different in the present study. Staining of the biopsies with the anti-type I collagen antibody did not reveal significant glomerular expression in any of the control or experimental groups (data not shown). In contrast, significant increases of the glomerular staining scores for type IV collagen, laminin, and fibronectin were noted in rats that had received a subnephritogenic ATS dose plus PDGF-BB or PDGF-BB + bFGF (Fig. 8) . In all other groups, the changes observed were not statistically different from the findings in vehicle-infused rats (Fig. 8) . Analysis of the glomerular expression of laminin B2 chain mRNA on day 7 after the start of the infusion in subnephritogenic ATS -A Figure 7 . Glomerular matrix expansion: silver methenamine staining of renal biopsies of subnephritogenic ATS rats that had received a seven day infusion of either vehicle (A) or PDGF-BB (B). A minor increase in mesangial silver staining is observed in the PDGF-BB infused rat. x400.
PDGF RECEPTOR B-SUBUNIT
rats revealed a 4.8-fold increase in PDGF-BB-infused rats, but not in those receiving bFGF or PDGF-BB plus bFGF (Fig. 9 ). Glomerular expression of type IV collagen mRNA was also increased in PDGF-BB infused rats, as well as in those receiving bFGF, but not in those receiving the combination of both ( Fig. 9) (relative increase over vehicle-infused rats: PDGF-BB, 2.8±0.6-fold; PDGF-BB + bFGF, 1.5±0.6-fold; bFGF, 2.5±1.1 -fold; all data corrected for the expression of 28S RNA; n = 3 each).
Effects ofPDGF-BB and bFGF infusion onfunctional renal parameters. No significant proteinuria (normal: < 10 mg/24 h) or increases in serum creatinine (normal: 40±4 pmol/ liter) or urea (normal: 8±0.8 mmol/liter) developed in any of the groups (data not shown).
Discussion
The data presented in this study show that the administration of bFGF (17 ng/min = IO-2 M/min) and in particular of PDGF-BB (28 ng/min = 10-2 M/min) can induce selective mesangial cell proliferation in the kidney, that this effect depends on the cellular status of the mesangial cell, that in cases ofmarked mesangial cell proliferation a concomittant overpro- 2958 Floege, Eng, Young, Alpers, Barrett, Bowen-Pope, and Johnson 
(3) (6) duction ofextracellular matrix occurs, and that neither mesangial cell proliferation nor matrix accumulation are associated with a functional renal impairment during the short period of the study. A main finding ofthis study was the selectivity ofthe induction of renal cell proliferation by PDGF and bFGF. Currently, no data exist on the renal cell types expressing receptors for bFGF in vivo. In vitro data, however, suggest that bFGF receptors are expressed by mesangial (10), glomerular endothelial (37), glomerular epithelial (38) , and tubular epithelial cells (39) , since it is mitogenic for these cell types. Immunohistochemical studies on the expression ofPDGF receptor f3 subunit in vivo have localized it to mesangial, parietal epithelial, and interstitial cells in human and primate kidneys (40) . In cell culture, PDGF is mitogenic for cultured mesangial cells (7) (8) (9) and papillary interstitial fibroblasts (41 ) . If bFGF and PDGF receptors are both expressed on a variety of renal cell types, what accounts for the selectivity of growth induction observed in the present study? In the case of bFGF, it is known from studies in vessels that only a previous injury renders cells, such as endothelial cells, responsive to the mitogenic effects ofbFGF (42) . These findings are consistent with our previous study (10) and with the present data, showing that only mesangial cells that had suffered a sublethal injury were growth responsive towards bFGF. Since the renal injury imposed by antiThy 1.1 antibody is specific for mesangial cells ( 15) , this might be an explanation for the selectivity ofbFGF-induced renal cell proliferation. In contrast to bFGF, PDGF-BB exerted mitogenic effects on mesangial cells in normal rat kidneys (although, again, mesangial injury increased the responsiveness). A concomittant increase in glomerular endothelial cell proliferation would not be expected since in normal human glomeruli no PDGF receptor f3 subunit could be demonstrated on endothelial cells (40) , and since bovine glomerular endothelial cells in vitro are nonresponsive towards PDGF (37) . Glomerular epithelial cells, despite producing PDGF B chain (43) , as well as proximal tubular epithelial cells in culture, have also been found to be nonresponsive to the mitogenic effect of PDGF (43, 44) . The lack of detectable interstitial growth induction may have been a technical problem during the early phase of the infusion period, since only cortical biopsies were obtained. Cortical, in contrast to papillary, fibroblasts have been found to be relatively resistant to PDGF-induced proliferation (41 ) . On the other hand, despite ongoing (though lesser) cell proliferation in glomeruli on day 7 ofthe PDGF infusion, no increased cell proliferation in the papillary tubulointerstitium was noted. In the present study, PDGF-BB turned out to be a more potent mesangial cell mitogen in vivo than bFGF. In vitro data suggest that both cytokines exert mitogenic effects of a similar order of magnitude on mesangial cells (8, 45) . However, these latter data were obtained in mesangial cells cultured under twodimensional conditions. Seeding of mesangial cells into a three-dimensional type I collagen matrix, in contrast, resulted in a complete loss ofthe mitogenic effect of PDGF (46) . These controversial observations point to the problems associated with extrapolating from in vitro findings to the in vivo situation and underline the requirement for in vivo studies when evaluating the potential actions of cytokines during disease.
A second central finding of this study was the increased cytokine responsiveness of mesangial cells after minor degrees of immune-mediated injury. Since anti-Thy 1.1 antibody not only recognizes mesangial cells, but also thymocytes and various extrarenal cells (47) , injection of the antibody might have led to release of substances from these latter cells that could have acted synergistically with the infused cytokines.
However, this seems unlikely, since the increased responsiveness in anti-Thy 1.1 injected rats persisted when the antibody was deposited locally within one kidney and did not enter the systemic circulation. A second possibility is that the injected anti-Thy 1.1 antibody might induce glomerular leukocyte or platelet influx via increased release of chemoattractants or increases of the local procoagulant activity (48, 49) . Both leukocytes and platelets contain potent mesangial cell growth factors ( 1, 4). Glomerular influx of inflammatory cells and increased thrombus formation induced by exogenously administered cytokines has been observed and may well be the explanation for findings in which the injection of interleukin-I augmented glomerular hypercellularity in murine IgA nephropathy (50) . In contrast, neither a glomerular influx of leukocytes nor thrombus formation was observed in the present study. Our observations suggest a third mechanism, namely changes of the status of the intrinsic glomerular tissue to explain the increased cytokine responsiveness after minor injury. It is unclear whether the mild increase in glomerular PDGF receptor expression observed after the injection of subnephritogenic amounts of ATS can account for the increased cytokine responsiveness. Several other possibilities also merit consideration, namely ATS-induced post-receptor modulation or injury-related changes of the extracellular matrix that facilitate access of the infused cytokines to the cells. Finally, changes of glomerular cell apoptosis in the subnephritogenic ATS rats could contribute to alterations of the total glomerular cellularity.
Several findings of the present study suggest that the mitogenic effects ofbFGF and PDGF-BB on mesangial cells in vivo were direct effects and not mediated via secondary mechanisms. No glomerular leukocyte or platelet influx, all of which contain potent mesangial cell mitogens ( 1, 4) , or glomerular thrombus formation, with thrombin representing another potent mesangial cell mitogen (1) , was observed in any of the groups. Furthermore, although not assessed by quantitative methods, we did not detect any apparent increase in the endogenous mesangial synthesis of PDGF B-chain. This latter finding contrasts with in vitro data showing that 10 ng/ml ofbFGF or PDGF-BB markedly increased the synthesis of PDGF B-chain in mesangial cells (8) . This discrepancy suggests that the local PDGF or bFGF concentrations achieved in our study may have been much lower than those used in the study of Silver et al. (8) , and that the PDGF induced mesangial cell proliferation in our study resided in an exogenous rather than an autocrine effect. In contrast to PDGF B chain, glomerular immunostaining for bFGF increased in parallel to the induction ofglomerular cell proliferation. Since this finding extended to both PDGF and bFGF infused rats, it did not appear to result from binding of infused bFGF to mesangial proteoglycans ( 10) . More likely, the increase in glomerular bFGF immunostaining was the consequence of an increase in the number of mesangial cells, which, in contrast to PDGF (22, 28) , constitutively express this cytokine in their cytoplasm ( 10) . This increase in endogenous glomerular bFGF expression, however, is unlikely to mediate the augmented mesangial cell proliferation, since bFGF is not a secreted cytokine, but rather, is released after sublethal or lethal mesangial cell injury (10) .
The last major finding of the present study was that the marked mesangial cell proliferation in vivo induced by PDGF-BB was associated with a moderate overproduction and accumulation of extracellular matrix, supporting the concept that cell proliferation and matrix overproduction frequently are coupled events ( 1, 27, 28) . In agreement with our in vivo findings, cell culture data have shown that PDGF increases the mesangial cell synthesis of fibronectin, laminin, type IV collagen, and heparan sulfate proteoglycan ( 11). The observation that PDGF-BB infused rats had an increase in glomerular laminin B2 chain and type IV collagen mRNA suggests that the accumulation of mesangial extracellular matrix was, in part, caused by upregulated synthesis. While the absence of increased laminin B2 chain mRNA in bFGF-infused rats may relate to the lower degree of cell proliferation, this cannot explain the absence of an increase of both laminin B2 chain and type IV collagen mRNA in rats infused with PDGF-BB plus bFGF, since mesangial cell proliferation in this group was as Interestingly, the increase in extracellular matrix components in PDGF-BB-and bFGF-infused rats was limited to components of the normal mesangial matrix. Neither interstitial (type I) collagen nor the expression of a-smooth muscle actin was induced, despite being present in several models ofglomerular diseases involving mesangial cell proliferation ( 15, 28) . This suggests that mesangial cell proliferation and matrix expansion can occur without the mesangial cell acquiring phenotypic characteristics of "myofibroblasts" ( 51 ) , and that other stimuli may be necessary (e.g., hemodynamic alterations or other cytokines) to induce these changes.
In conclusion, this study provides further evidence that PDGF and (to a lesser degree) bFGF may be involved in the increased mesangial cell proliferation and matrix expansion that occurs in a variety of glomerular diseases. Our findings also show that sublethal injury to glomeruli that has no, or only minimal, morphological correlates may induce glomerular changes of a yet undefined nature, that render the cells more responsive to the action of inflammatory mediators. From a clinical point of view, this might explain how a minor renal insult could have pronounced effects in the presence of a subclinical but ongoing autoimmune process. Finally, this study provides a further rationale to examine the effects of PDGF or bFGF antagonists on the course of progressive glomerular disease. However, as discussed elsewhere in more detail (5), before such interventional trials are undertaken, more insight into the question will have to be gained of when and how the physiological, (e.g., regenerative) role of cytokines becomes a pathological one.
